BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang L, Pei RJ, Li H, Ma XN, Zhou Y, Zhu FH, He PL, Tang W, Zhang YC, Xiong J, Xiao SQ, Tong XK, Zhang B, Zuo JP. Identification of SARS-CoV-2 entry inhibitors among already approved drugs. Acta Pharmacol Sin 2021;42:1347-53. [PMID: 33116249 DOI: 10.1038/s41401-020-00556-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu X, Cheng T, Liu B, Chi J, Shu T, Wang T. Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development. Front Pharmacol 2022;13:955648. [DOI: 10.3389/fphar.2022.955648] [Reference Citation Analysis]
2 Laise P, Stanifer ML, Bosker G, Sun X, Triana S, Doldan P, La Manna F, De Menna M, Realubit RB, Pampou S, Karan C, Alexandrov T, Kruithof-de Julio M, Califano A, Boulant S, Alvarez MJ. A model for network-based identification and pharmacological targeting of aberrant, replication-permissive transcriptional programs induced by viral infection. Commun Biol 2022;5:714. [PMID: 35854100 DOI: 10.1038/s42003-022-03663-8] [Reference Citation Analysis]
3 Travi BL. Current status of antihistamine drugs repurposing for infectious diseases. Medicine in Drug Discovery 2022. [DOI: 10.1016/j.medidd.2022.100140] [Reference Citation Analysis]
4 Konrat R, Papp H, Kimpel J, Rössler A, Szijártó V, Nagy G, Madai M, Zeghbib S, Kuczmog A, Lanszki Z, Gesell T, Helyes Z, Kemenesi G, Jakab F, Nagy E. The Anti-Histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits Infection by Major Variants of SARS-CoV-2 in Cell Cultures and Reconstituted Human Nasal Tissue. Front Pharmacol 2022;13:861295. [DOI: 10.3389/fphar.2022.861295] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Oh K, Adnan M, Cho D. Network Pharmacology Study to Elucidate the Key Targets of Underlying Antihistamines against COVID-19. CIMB 2022;44:1597-609. [DOI: 10.3390/cimb44040109] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Wang L, Wu Y, Yao S, Ge H, Zhu Y, Chen K, Chen WZ, Zhang Y, Zhu W, Wang HY, Guo Y, Ma PX, Ren PX, Zhang XL, Li HQ, Ali MA, Xu WQ, Jiang HL, Zhang LK, Zhu LL, Ye Y, Shang WJ, Bai F. Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. Acta Pharmacol Sin 2022;43:788-96. [PMID: 34349236 DOI: 10.1038/s41401-021-00735-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
7 González-Maldonado P, Alvarenga N, Burgos-Edwards A, Flores-Giubi ME, Barúa JE, Romero-Rodríguez MC, Soto-Rifo R, Valiente-Echeverría F, Langjahr P, Cantero-González G, Sotelo PH. Screening of Natural Products Inhibitors of SARS-CoV-2 Entry. Molecules 2022;27:1743. [PMID: 35268843 DOI: 10.3390/molecules27051743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
8 Sencanski M, Perovic V, Milicevic J, Todorovic T, Prodanovic R, Veljkovic V, Paessler S, Glisic S. Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach. ChemistryOpen 2022;11:e202100248. [PMID: 35103413 DOI: 10.1002/open.202100248] [Reference Citation Analysis]
9 Xiang Q, Li L, Wu J, Tian M, Fu Y. Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. Microbiological Research 2022. [DOI: 10.1016/j.micres.2022.126993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Fred SM, Kuivanen S, Ugurlu H, Casarotto PC, Levanov L, Saksela K, Vapalahti O, Castrén E. Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro. Front Pharmacol 2022;12:755600. [DOI: 10.3389/fphar.2021.755600] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
11 Ma X, Li H, Gong Y, Liu F, Tong X, Zhu F, Yang X, Yang L, Zuo J. Psoralen inhibits hepatitis B viral replication by down-regulating the host transcriptional machinery of viral promoters. Virologica Sinica 2022. [DOI: 10.1016/j.virs.2022.01.027] [Reference Citation Analysis]
12 Sharma PP, Bansal M, Sethi A, Poonam, Pena L, Goel VK, Grishina M, Chaturvedi S, Kumar D, Rathi B. Computational methods directed towards drug repurposing for COVID-19: advantages and limitations. RSC Adv 2021;11:36181-98. [PMID: 35492747 DOI: 10.1039/d1ra05320e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Chu J, Xing C, Du Y, Duan T, Liu S, Zhang P, Cheng C, Henley J, Liu X, Qian C, Yin B, Wang HY, Wang RF. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. Nat Metab 2021;3:1466-75. [PMID: 34580494 DOI: 10.1038/s42255-021-00479-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
14 Dogan K, Erol E, Didem Orhan M, Degirmenci Z, Kan T, Gungor A, Yasa B, Avsar T, Cetin Y, Durdagi S, Guzel M. Instant determination of the artemisinin from various Artemisia annua L. extracts by LC-ESI-MS/MS and their in-silico modelling and in vitro antiviral activity studies against SARS-CoV-2. Phytochem Anal 2021. [PMID: 34585460 DOI: 10.1002/pca.3088] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Javelot H, Straczek C, Meyer G, Gitahy Falcao Faria C, Weiner L, Drapier D, Fakra E, Fossati P, Weibel S, Dizet S, Langrée B, Masson M, Gaillard R, Leboyer M, Llorca PM, Hingray C, Haffen E, Yrondi A. Psychotropics and COVID-19: An analysis of safety and prophylaxis. Encephale 2021;47:564-88. [PMID: 34548153 DOI: 10.1016/j.encep.2021.08.002] [Reference Citation Analysis]
16 Guo Y, Meng JR, Liu JZ, Xu T, Zheng ZY, Jiang ZH, Bai LP. Synthesis and Biological Evaluation of Honokiol Derivatives Bearing 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol-2(3H)-ones as Potential Viral Entry Inhibitors against SARS-CoV-2. Pharmaceuticals (Basel) 2021;14:885. [PMID: 34577585 DOI: 10.3390/ph14090885] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
17 Muhammed Y, Yusuf Nadabo A, Pius M, Sani B, Usman J, Anka Garba N, Mohammed Sani J, Opeyemi Olayanju B, Zeal Bala S, Garba Abdullahi M, Sambo M. SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: A review. Biosaf Health 2021. [PMID: 34396086 DOI: 10.1016/j.bsheal.2021.07.003] [Reference Citation Analysis]
18 Loas G, Le Corre P. Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection. Pharmaceuticals (Basel) 2021;14:691. [PMID: 34358117 DOI: 10.3390/ph14070691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
19 Welch SR, Spengler JR, Genzer SC, Chatterjee P, Flint M, Bergeron É, Montgomery JM, Nichol ST, Albariño CG, Spiropoulou CF. Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform. Viruses 2021;13:1255. [PMID: 34203149 DOI: 10.3390/v13071255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV 3rd, Kwon DH, Singh T, Tilton JC, Tsai EJ, Tucker NR, Barnard J, Loscalzo J. COVID-19 and Cardiovascular Disease: From Bench to Bedside. Circ Res 2021;128:1214-36. [PMID: 33856918 DOI: 10.1161/CIRCRESAHA.121.317997] [Cited by in Crossref: 14] [Cited by in F6Publishing: 59] [Article Influence: 14.0] [Reference Citation Analysis]
21 Chen M, Zhang XE. Construction and applications of SARS-CoV-2 pseudoviruses: a mini review. Int J Biol Sci 2021;17:1574-80. [PMID: 33907521 DOI: 10.7150/ijbs.59184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
22 Day CJ, Bailly B, Guillon P, Dirr L, Jen FE, Spillings BL, Mak J, von Itzstein M, Haselhorst T, Jennings MP. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions. mBio 2021;12:e03681-20. [PMID: 33785634 DOI: 10.1128/mBio.03681-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
23 Hou Y, Ge S, Li X, Wang C, He H, He L. Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis. Chem Biol Interact 2021;338:109420. [PMID: 33609497 DOI: 10.1016/j.cbi.2021.109420] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
24 Gitahy Falcao Faria C, Weiner L, Petrignet J, Hingray C, Ruiz De Pellon Santamaria Á, Villoutreix BO, Beaune P, Leboyer M, Javelot H. Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19? Med Hypotheses 2021;148:110508. [PMID: 33571758 DOI: 10.1016/j.mehy.2021.110508] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
25 Mirabelli C, Wotring JW, Zhang CJ, McCarty SM, Fursmidt R, Frum T, Kadambi NS, Amin AT, O'Meara TR, Pretto CD, Spence JR, Huang J, Alysandratos KD, Kotton DN, Handelman SK, Wobus CE, Weatherwax KJ, Mashour GA, O'Meara MJ, Sexton JZ. Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19. bioRxiv 2020:2020. [PMID: 32577649 DOI: 10.1101/2020.05.27.117184] [Cited by in Crossref: 37] [Cited by in F6Publishing: 9] [Article Influence: 18.5] [Reference Citation Analysis]